On Innovation.
Innovation has become an increasingly common topic in healthcare. Private companies, developers, payers, and regulators are devoting attention toward innovative products and processes as a crucial component of their interests in and occupation with healthcare services. Even when there is no consensu...
| Publicado en: | Therapeutic Innovation & Regulatory Science Vol. 54; no. 5; pp. 1068 - 1076 |
|---|---|
| Autor principal: | |
| Formato: | review tables/charts Journal Article |
| Publicado: |
Springer Nature
Sep2020
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=145405375&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 145405375 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 21684790 FUHO jtl: Therapeutic Innovation & Regulatory Science issn: 21684790 maglogo: N pubinfo: dt: Sep2020 vid: 54 iid: 5 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 145405375 143971782 145405375 145405375 10.1007/s43441-020-00125-3 145405375 ppf: 1068 ppct: 8 formats: tig: atl: On Innovation. aug: au: Belloso, Waldo H. affil: National Administration of Drugs, Food and Medical Technology, Buenos Aires, Argentina sug: subj: Diffusion of Innovation Implementation Science Government Regulations Multidisciplinary Care Team Uncertainty Consensus ab: Innovation has become an increasingly common topic in healthcare. Private companies, developers, payers, and regulators are devoting attention toward innovative products and processes as a crucial component of their interests in and occupation with healthcare services. Even when there is no consensus as to its definition, "innovation" —as opposed to "invention"— is broadly understood to refer turning a good idea into a practical solution. Adoption and applicability are key components of implementation that are sustained not only on innovation's attributes themselves but also in the characteristics of providers, users, and implementing organizations, as well as the external environment. Regulatory agencies often face the need to make decisions about proposed innovations with obsolete or inadequate normative frameworks and with a high degree of uncertainty about its eventual performance or its risks. Early interaction between developers and dedicated multidisciplinary teams at regulatory agencies may prove instrumental for speeding up the time required for proper evaluation and product registration, as well as the establishment of quality validation mechanisms. Community involvement both in the adoption and vigilance on innovative products and processes is crucial for completing the process of defining their roles and uses. pubtype: Academic Journal doctype: review tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|